Akebia Therapeutics (AKBA) Preferred Stock Liabilities (2013)
Akebia Therapeutics' (AKBA) quarterly Preferred Stock Liabilities came in at $157.8 million in Q4 2013.
Akebia Therapeutics (AKBA) Preferred Stock Liabilities (2013) Analysis & Trends
Akebia Therapeutics (AKBA) has 1 years of Preferred Stock Liabilities data on file, last reported at $157.8 million in Q4 2013.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $157.8 million in Q4 2013; TTM through Dec 2013 was $157.8 million, a N/A change from a year earlier, with the FY2013 full-year figure at $157.8 million, up 696.46% from the prior year.
- Preferred Stock Liabilities for Q4 2013 stood at $157.8 million.
- Over the last five years, Preferred Stock Liabilities for AKBA reached as high as $157.8 million in Q4 2013 and fell as low as $157.8 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Akebia Therapeutics | 325.80 Mn | 163.20 Mn | 41.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 157.83 Mn |